Romero A, Barrachina L, Ranera B, Remacha A R, Moreno B, de Blas I, Sanz A, Vázquez F J, Vitoria A, Junquera C, Zaragoza P, Rodellar C
Laboratorio de Genética Bioquímica (LAGENBIO), Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, 50013 Zaragoza, Spain; Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, 50013 Zaragoza, Spain.
Laboratorio de Genética Bioquímica (LAGENBIO), Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, 50013 Zaragoza, Spain.
Vet J. 2017 Jun;224:76-84. doi: 10.1016/j.tvjl.2017.04.005. Epub 2017 May 2.
Several therapies have been investigated for equine tendinopathies, but satisfactory long term results have not been achieved consistently and a better understanding of the healing mechanism elicited by regenerative therapies is needed. The aim of this study was to assess the separate effects of autologous bone marrow (BM) and adipose tissue (AT) derived mesenchymal stem cells (MSCs), and platelet rich plasma (PRP), for treating lesions induced in the superficial digital flexor tendon (SDFT) of horses. Lesions were created surgically in both SDFTs of the forelimbs of 12 horses and were treated with BM-MSCs (six tendons), AT-MSCs (six tendons) or PRP (six tendons). The remaining six tendons received lactated Ringer's solution as control. Serial ultrasound assessment was performed prior to treatment and at 2, 6, 10, 20 and 45 weeks post-treatment. At 45 weeks, histopathology and gene expression analyses were performed. At week 6, the ultrasound echogenicity score in tendons treated with BM-MSCs suggested earlier improvement, whilst all treatment groups reached the same level at week 10, which was superior to the control group. Collagen orientation scores on histological examination suggested a better outcome in treated tendons. Gene expression was indicative of better tissue regeneration after all treatments, especially for BM-MSCs, as suggested by upregulation of collagen type I, decorin, tenascin and matrix metalloproteinase III mRNA. Considering all findings, a clear beneficial effect was elicited by all treatments compared with the control group. Although differences between treatments were relatively small, BM-MSCs resulted in a better outcome than PRP and AT-MSCs.
针对马的肌腱病已研究了多种治疗方法,但尚未始终如一地取得令人满意的长期效果,因此需要更好地了解再生疗法引发的愈合机制。本研究的目的是评估自体骨髓(BM)和脂肪组织(AT)来源的间充质干细胞(MSCs)以及富血小板血浆(PRP)对治疗马的指浅屈肌腱(SDFT)损伤的单独作用。在12匹马的前肢双侧SDFT上手术制造损伤,并分别用BM-MSCs(6条肌腱)、AT-MSCs(6条肌腱)或PRP(6条肌腱)进行治疗。其余6条肌腱接受乳酸林格氏液作为对照。在治疗前以及治疗后2、6、10、20和45周进行系列超声评估。在45周时,进行组织病理学和基因表达分析。在第6周时,用BM-MSCs治疗的肌腱的超声回声评分显示改善较早,而所有治疗组在第10周时达到相同水平,且均优于对照组。组织学检查的胶原取向评分表明治疗后的肌腱预后更好。基因表达表明所有治疗后组织再生情况更好,尤其是BM-MSCs,如I型胶原、核心蛋白聚糖、肌腱蛋白和基质金属蛋白酶III mRNA的上调所示。综合所有研究结果,与对照组相比,所有治疗均产生了明显的有益效果。尽管治疗之间的差异相对较小,但BM-MSCs的效果优于PRP和AT-MSCs。